Astrazeneca vs Bristol Myers Squibb
Astrazeneca is the larger business, with $58.74bn of revenue in fiscal 2025 against $48.19bn for Bristol Myers Squibb (1.2 times as much). Astrazeneca grew faster (8.6% against -0.2%). Astrazeneca kept more of each dollar of sales as profit: a net margin of 17.4% against 14.6%. Astrazeneca carries less debt relative to equity (60.9% against 254.9%).
| Latest fiscal year | AstrazenecaAZN, 2025 | Bristol Myers SquibbBMY, 2025 |
|---|---|---|
| Revenue | $58.74bn | $48.19bn |
| Revenue growth | 8.6% | -0.2% |
| Net income | $10.22bn | $7.05bn |
| Operating margin | 23.4% | — |
| Net margin | 17.4% | 14.6% |
| Return on equity | 22.9% | 40.5% |
| Free cash flow | $11.77bn | $12.85bn |
| Cash | $5.71bn | $10.21bn |
| Total debt | $29.62bn | $47.09bn |
| Debt to equity | 60.9% | 254.9% |
| Dividend per share | — | $2.49 |
| Dividend yield | 1.7% | 4.0% |
| Share buybacks | $521m | $0 |
| Employees | — | 32,500 |
| Market value | $286.25bn | $126.73bn |
| Price vs our value range | Within our value range | Below our value range |
| Moat score | — | 77 (Strong) |
| Insider trades, 12 months | 1 buys, 1 sales | 0 buys, 4 sales |